Pronabive, the National Producer of Veterinary Biologicals in Mexico, aims to produce 21.05 million doses of biologicals for the livestock sector in 2023, with a focus on Mexico and Central and South America. This is an increase from the 14.5 million units produced in 2022. Pronabive's product portfolio includes vaccines and diagnostic reagents for various animal diseases such as brucellosis, equine encephalitis, and bovine tuberculosis. These products are distributed through partnerships with state committees, organizations, and the Mexican veterinary pharmaceutical industry. The company's work is seen as crucial for supporting nations like Guatemala, Argentina, and Brazil in health matters, contributing to their security and enabling the continuation of livestock trade with more than 190 countries.